ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

INDIA CEMENTS-Rise in Demand

EPW Research Foundation RANBAXY LABORATORIES Focus on R and D RANBAXY, one of India's largest pharmaceutical companies, achieved a sales turnover of Rs 666 crore for the year ended March 1995, up by 19 per cent from Rs 561 crore in the corresponding period in 'the previous year. Other income rose from Rs 2 crore to Rs 9 crore taking total income to Rs 704 crore up by 24 per cent from Rs 565 crore in the previous year. As in the previous year, the company incurred zero interest costs. Provision for lax and for depreciation rose by 29 per cent and 953 per cent, respectively. Nevertheless the company caded up with a net profit of Rs 110crore, up by 74 per cent from Rs 63 crore in the previous year. A major contribution to the boliomlme came in the form of non-' operating profit of Rs 20 crore against a loss incurred in the previous year on this count. A dividend of 30 per cent has been recommended by the directors, Ranbaxy has eight technologically advanced plants which have been designed to international specifications. The company has a state-of-the-art instrumentation system for chemical and sterility testing and an online system for material management, inventory control and produclion planning resulting in lower costs, increased productivity, as well as consistent product quality. The company has a strong distribution . network being able to reach customers through more than 1,400 stockists.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top